Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. It offers physiology, cell, and molecular instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. The company also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products, systems, services, and solutions with a focus on physiologic monitoring solutions. It markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. The company primarily sells its products under Harvard Apparatus, Biochrom, Hoefer, Panlab, Warner Instruments, Hugo Sachs Elektronik, Scie-Plas, BTX, Multi Channel Systems, HEKA, DSI, Ponemah, and Buxco brand names in North America, Europe, China, and internationally. Harvard Bioscience, Inc. was founded in 1901 and is headquartered in Holliston, Massachusetts.
IPO Year: 2000
Exchange: NASDAQ
Website: harvardbioscience.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/10/2023 | $3.00 → $4.00 | Speculative Buy → Buy | The Benchmark Company |
HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2024. Jim Green, Chairman and CEO, said, "Our fourth quarter saw sequential strengthening in pre-clinical revenues across all regions, while our cellular and molecular technology (CMT) revenues were down slightly from the third quarter, primarily due to reduced purchasing by US academic customers. As expected, our fourth quarter revenues were down compared to the fourth quarter of last year as we navigated a challenging market environment. Green continued, "We are encouraged by the strong mark
HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended December 31, 2024, before the market opens on March 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentati
HOLLISTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the third quarter ended September 30, 2024. Jim Green, Chairman and CEO, said, "Our third quarter revenues continued to reflect the effects of the challenging market environment. Our migration to a single US enterprise resource planning system, completed in the third quarter, supports operating efficiencies as well as improvements in inventory and supply chain management going forward. We have stayed focused on managing costs and have implemented additional cost reduction actions that we expect to result in incremental quarterly cost savings of
HOLLISTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended September 30, 2024 before the market opens on November 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presenta
HOLLISTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the second quarter ended June 30, 2024. Jim Green, Chairman and CEO, said, "Second quarter revenues reflect a more challenging than expected market environment. With the uncertainty of the timing for market recovery we stayed focused on managing costs and the actions we implemented during Q2 are expected to drive annualized savings of approximately $4 million while we continue our work on new product development and growth initiatives." Green continued, "We believe the market recovery is likely delayed to later in the second half however we rema
HOLLISTON, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended June 30, 2024 before the market opens on August 8, 2024, and will hold a conference call to discuss the results at 10:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presenta
HOLLISTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the first quarter ended March 31, 2024. Jim Green, Chairman and CEO, said, "As expected, our first quarter revenues reflect ongoing market headwinds, especially in APAC, amplified by a strong prior year comparison. Despite these headwinds, we were pleased to deliver gross margins of 60%. After quarter end, we announced a cost reduction initiative to improve our operating cost structure and support our ongoing investments in growth." Green continued, "Looking ahead, we are excited by our growth strategy and new product commercializations. Together
HOLLISTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended March 31, 2024 before the market opens on May 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentation, wi
Q4 Revenues of $28.2 millionQ4 Gross Margin of 58.0% (230 bps year-over-year improvement)Q4 operating income of $0.3 million, adjusted operating income of $3.3 millionStrong operating cash flow enabled 2023 debt reduction of $10.5 million and a significant decrease in net leverage HOLLISTON, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the fourth quarter and year ended December 31, 2023. Jim Green, Chairman and CEO said, "Our fourth quarter revenue was down a modest 1% compared to the prior year quarter in a challenging APAC marketplace. Revenue included a net reduction of approximately $0.9 million
HOLLISTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended December 31, 2023 before the market opens on March 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentation,
The Benchmark Company upgraded Harvard Biosci from Speculative Buy to Buy and set a new price target of $4.00 from $3.00 previously
KeyCorp reiterated coverage of Harvard Bioscience with a rating of and set a new price target of $9.00 from $6.00 previously
HOLLISTON, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced the appointment of Jennifer Cote as the Company's Chief Financial Officer and Treasurer, effective June 19, 2023. Cote joined the Company as Vice President of Global Finance in May 2022 and has served as Interim Chief Financial Officer and Treasurer since January 2023. Jim Green, Chairman and CEO said, "Originally joining us as our Vice President of Global Finance, Jennifer brought extensive experience in areas including global financial and operational leadership, corporate strategy, accounting and internal controls, and strong fiscal management. Since assuming the
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
SCHEDULE 13G - HARVARD BIOSCIENCE INC (0001123494) (Subject)
SCHEDULE 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)
EFFECT - HARVARD BIOSCIENCE INC (0001123494) (Filer)
S-3 - HARVARD BIOSCIENCE INC (0001123494) (Filer)
10-Q - HARVARD BIOSCIENCE INC (0001123494) (Filer)
8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
10-Q - HARVARD BIOSCIENCE INC (0001123494) (Filer)
8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)
SD - HARVARD BIOSCIENCE INC (0001123494) (Filer)
HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will participate in two investor conferences in March 2025: The 37th Annual Roth Conference is being held on March 16-18, 2025, at the Laguna Cliffs Marriott Resort in Dana Point, CA. On March 17th, management will host one-on-one meetings and is scheduled for a Fireside Chat on the same day starting at 10 a.m. PT (1:00 p.m. ET). The live webcast is available on HBIO's website at https://investor.harvardbioscience.com/events-and-presentations. Investors interested in scheduling a one-on
HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2024. Jim Green, Chairman and CEO, said, "Our fourth quarter saw sequential strengthening in pre-clinical revenues across all regions, while our cellular and molecular technology (CMT) revenues were down slightly from the third quarter, primarily due to reduced purchasing by US academic customers. As expected, our fourth quarter revenues were down compared to the fourth quarter of last year as we navigated a challenging market environment. Green continued, "We are encouraged by the strong mark
HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced that it will be showcasing its latest product innovations at the Society of Toxicology (SOT) conference from March 17-20, 2025, in Orlando. Building upon its comprehensive product portfolio, these latest developments open promising new avenues for progressing preclinical research and organoid-based therapeutic development. Expansion of SoHo™ Implantable Real-Time Telemetry Platform The SoHo telemetry solution enables researchers to collect, manage, analyze and report findings from multiple concurrent small animal models in both shared housing and extended range environments. The
HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended December 31, 2024, before the market opens on March 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentati
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 22-23, 2025. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.Presentation Schedule*All Times ESTWednesday, January 22, 2025 (Day 1)8:30-9:00Rectitude Holdings Ltd (RECT)*****9:15-9:45Rezolve AI (RZLV)Alico (ALCO)10:00-10:30Harvard Bioscience (HBIO)Flotek Industries (FTK)10:45-11:15Amesite Inc. (AMST)*****11:30-12:00*****Forum Energy Technologies Inc (FET)12:15-12
HOLLISTON, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Sidoti Micro Cap Virtual Conference on January 22nd, 2025, with a presentation time of 10:00 am ET. The presentation will be webcast live and can be accessed through the investor relations section of the Harvard Bioscience website: https://investor.harvardbioscience.com/events-and-presentations. A replay will be available on the company's website shortly after the presentation has concluded. To schedule a one-on-one meeting, please contact the conference
HOLLISTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the third quarter ended September 30, 2024. Jim Green, Chairman and CEO, said, "Our third quarter revenues continued to reflect the effects of the challenging market environment. Our migration to a single US enterprise resource planning system, completed in the third quarter, supports operating efficiencies as well as improvements in inventory and supply chain management going forward. We have stayed focused on managing costs and have implemented additional cost reduction actions that we expect to result in incremental quarterly cost savings of
HOLLISTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended September 30, 2024 before the market opens on November 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presenta
HOLLISTON, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) 2024 Annual Meeting being held October 5 - 9 in Chicago. Cutting-edge innovations on display include the revolutionary new Mesh MEA™ microelectrode array system, the SoHo™ implantable telemetry platform, and the VivaMARS™ activity monitoring system. MCS™ Mesh MEA™ Organoid Platform The Company will exhibit its organoid-centric mesh Microelectrode Array (MEA) platform, which continues to gain traction among the scientific and therapy development communities. Unlike traditional technologies
HOLLISTON, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) today announced that it will be showcasing its latest product innovations at the Safety Pharmacology Society (SPS) Annual Meeting being held from September 22-25, 2024, in San Diego. DSI™ Ponemah™ Data Management Platform Provides Integrated Preclinical Solution The Company's Ponemah™ platform, known for its compliance with GLP standards, is a leading tool for managing and analyzing data from a wide range of preclinical studies. It now integrates with DSI's SoHo™ implantable telemetry and high-capacity VivaMARS™ behavior monitoring systems. Ponemah is the top solution for collecting and processing
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)
SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)
SC 13G - HARVARD BIOSCIENCE INC (0001123494) (Subject)
SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)
SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)
SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)
SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Filed by)
SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)
SC 13G - HARVARD BIOSCIENCE INC (0001123494) (Subject)
SC 13G/A - HARVARD BIOSCIENCE INC (0001123494) (Subject)
SC 13G - HARVARD BIOSCIENCE INC (0001123494) (Subject)